· The CHMP positive opinion marks the first time a monoclonal antibody treatment for COVID-19 has received a recommendation for marketing authorisation from the EMA
· The recommendation is based on data from the global Phase III clinical trial investigating regdanvimab as a treatment for multiple variants of COVID-19, including the Delta variant
· Regdanvimab is the first authorised COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS); More than 21,366 people treated with regdanvimab in 127 hospitals in the Republic of Korea
INCHEON, Korea, Nov 15 (Bernama-BUSINESS WIRE) — Celltrion Group announced today that the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59), a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. The CHMP positive opinion is a scientific recommendation to the European Commission (EC), which authorises marketing approval in the European Union.
- Yemen’s Houthis Target Israel’s Main Airport Three Times Within 48 Hours
- Urgent: Yemen’s Houthis Claim Missile Attack On Israel’s Ben Gurion Airport
- U.S. New Anti-Iran Sanctions Not Compatible With Nuclear Talks: Spokesman
- Islamic Jihad Launches Rockets At Israeli Cities In Response To Gaza Hospital Strikes
- More than 83 mn people internally displaced worldwide: monitor
- One Killed, 12 Injured In Hand Grenade Attack In SW Pakistan
- Pakistan, India Expel Each Other’s Diplomats
- DPRK Top Leader Inspected Combined Tactical Drill Of Different Arms
- Australian PM Albanese, Ministers Sworn In Following Election Victory
- Moderate Candidate Ley Wins Leadership Of Australia’s Conservative Opposition Party